Department of Pediatrics, Pt. BD Sharma Post Graduate Institute of Medical Sciences (Pt BDS-PGIMS), Rohtak, Haryana, 124001, India.
The Wellcome Trust Research Laboratory, Christian Medical College (CMC), Vellore, Tamil Nadu, India.
Indian J Pediatr. 2021 Mar;88(Suppl 1):10-15. doi: 10.1007/s12098-020-03614-3. Epub 2021 Jan 14.
To evaluate the epidemiology of rotavirus gastroenteritis in Haryana post-introduction of rotavirus vaccine. Expanded National rotavirus surveillance network in India reported high burden of rotavirus diarrhea in India. The Government of India introduced the monovalent rotavirus vaccine made in India by Bharat Biotech in the national immunization programme from 2016 onward along with oral polio vaccine (OPV) and Pentavalent vaccines.
A multi-centric, hospital-based surveillance study in the initial vaccine introducing states was started in a phased manner over a period of 3 y. PGIMS, Rohtak is a tertiary care center and was a part of the surveillance from 2016 to 2019. Children aged 0-59 mo admitted with acute gastroenteritis were enrolled into the surveillance and their stool samples were collected. Samples were tested at Christian Medical College (CMC), Vellore to detect rotavirus and reverse transcription-polymerase chain reaction (RT-PCR) was used for G and P typing.
A total of 904 children were enrolled in the present surveillance over a period of 3 y starting 1st July 2016 to 30th June 2019. Stool samples were collected and analyzed for 827 children and out of them 141 samples were positive for rotavirus (17.1%). Maximum rotavirus positivity was observed during the winter months. Rotavirus positivity percentage was observed maximum in 12-23 mo age group. A declining trend was observed in rotavirus positivity from 22.8% in 2016 to 14.5% in 2019. Most common strains of rotavirus isolated were G3P[8] followed by G1P[8].
This study highlights that epidemiology of acute gastroenteritis among children less than 5 y of age in Haryana postintroduction of rotavirus vaccination in the state and the decline in rotavirus positivity from 22.8% in 2016 to 14.5% in 2019.
评估在引入轮状病毒疫苗后哈里亚纳邦轮状病毒肠胃炎的流行病学情况。在印度，扩大的国家轮状病毒监测网络报告了印度轮状病毒腹泻的高负担。印度政府于 2016 年起在国家免疫规划中引入了印度 Bharat Biotech 生产的单价轮状病毒疫苗，同时还引入了口服脊髓灰质炎疫苗（OPV）和五价疫苗。
在最初引入疫苗的州，以分阶段的方式开始了一项多中心、以医院为基础的监测研究，历时 3 年。PGIMS，罗塔克是一家三级保健中心，从 2016 年到 2019 年参与了监测。收治的 0-59 月龄因急性肠胃炎入院的儿童被纳入监测，并采集其粪便样本。样本在基督教医学院（CMC），维洛尔进行检测以检测轮状病毒，并使用逆转录-聚合酶链反应（RT-PCR）进行 G 和 P 型分型。
在 2016 年 7 月 1 日至 2019 年 6 月 30 日期间，本监测共纳入 904 名儿童，历时 3 年。共采集并分析了 827 名儿童的粪便样本，其中 141 份样本检测出轮状病毒阳性（17.1%）。轮状病毒阳性率最高的月份是冬季。12-23 月龄组轮状病毒阳性率最高。轮状病毒阳性率从 2016 年的 22.8%下降到 2019 年的 14.5%。分离出的最常见轮状病毒株是 G3P[8]，其次是 G1P[8]。
本研究强调了哈里亚纳邦在引入轮状病毒疫苗后，5 岁以下儿童急性肠胃炎的流行病学情况，以及轮状病毒阳性率从 2016 年的 22.8%下降到 2019 年的 14.5%。
